Advanced tumors, usually with multiple metastases throughout the body, cannot be controlled by means of surgery or radiotherapy, and only chemotherapy or targeted therapy can control the disseminated tumor cells. Clinical practice confirms that targeted therapy is only applicable to a small number of people, while chemotherapy patients can usually only improve their survival time by one to two months compared to those without chemotherapy, but at the cost of significantly lower quality of survival and high treatment costs. From a humanistic point of view, chemotherapy is an option that does not pay off. 2015 latest medical advances, patients with advanced tumors have a new option – immunotherapy. Recent studies suggest suggest that effective tumor immunotherapy strategies aim to promote the tumor-immune cycle and relieve the immunosuppressive effects of established tumors. Common immunotherapeutic tools include cytokines (which promote dendritic cell maturation and T cell differentiation), checkpoint inhibitors (which prevent T cell unresponsiveness), toll-like receptor agonists, oncolytic viruses (which induce necrotic tumor cell death, release risk-associated molecules patterns (DAMPs), activation of systemic autoimmunity), primary T cells, and transgenic T cell passages (which can recognize specific tumor antigens through T cell receptors). Vaccines have also been intensively investigated because of their ability to activate T cells. However, vaccines do not have significant anti-tumor activity, perhaps because they do not resist immunosuppression in the tumor microenvironment. The renowned Le team in the United States conducted a randomized phase II clinical trial in which they optimized immunotherapy with a more rational design and a more precise approach. They evaluated the efficacy of cyclophosphamide-tumor vaccine (GVAX) therapy, as well as cyclophosphamide-tumor vaccine-recombinant Listeria monocytogenes combination therapy in patients with pancreatic cancer. GVAX is an inactivated granulocyte-macrophage colony-stimulating factor (GM-CSF)-encoded allogeneic tumor cell vaccine. The details of the immunotherapy combination were that cyclophosphamide was administered concomitantly with the tumor vaccine, followed by injection of large amounts of live recombinant Listeria monocytogenes, which expresses mesothelin and releases it into the cytoplasm of antigen-presenting cells. Sixty-one patients were treated with a combination of cyclophosphamide-tumor vaccine-recombinant Listeria monocytogenes and 29 patients with cyclophosphamide-tumor vaccine. There were no objective remissions (objectiveresponses) before or after treatment in either group, but overall survival was significantly higher in the combination group (9.7 months vs. 4.6 months, P=0.02). This may be associated with increased levels of mesothelin-specific CD8+ T-cell responses. This study shows that even difficult-to-treat advanced pancreatic cancer responds therapeutically to tumor immunotherapy. This study combined multiple therapeutic modalities to improve treatment outcomes, such as reducing regulatory T cell levels with cyclophosphamide (pancreatic cancer), activating initial T cell responses with allogeneic whole cell vaccines, promoting local dendritic cell aggregation and maturation through the release of GM-CSF, activating toll-like receptors and innate immunity with intracellular bacteria, and upregulating antigen-presenting intercellular responses, upregulation of antigen-presenting cell mesothelin expression levels to initiate antigen-specific T-cell responses. Although no objective remission occurred in this study, the results of the predefined analysis of overall survival were promising. It is a common feature of immunotherapy trials that no objective remission or progression-free survival is observed, possibly due to delayed kinetics in therapeutic response. Therefore, when designing new clinical trials, it is advisable to use overall survival or other endpoint outcomes as indicators to assess the potential efficacy of tumor immunotherapy. Importantly, tumor immunotherapy is well tolerated compared to chemoradiotherapy. The most common adverse effects in immunotherapy are limited to fever, lymphopenia, fatigue, and elevated liver enzyme levels. This may be related to the presence of GM-CSF in immunotherapy drugs. Currently cellular immunotherapy for oncology has been abandoned in Europe and the United States due to its unassessable efficacy. To quote the originator of cellular immunotherapy for tumors: I don’t know where the immune cells expanded in vitro go, the only thing that is certain is that they do not concentrate in the tumor lesion. The clinical practice strategy of tumor immunotherapy: break local tumor immune tolerance by means of mild chemotherapeutic drugs or radiotherapy, etc., and at the same time, inactivate by UV light after in vitro expansion of own tumor cells, product + GM-CSF subcutaneous treatment injection. Followed by subcutaneous injection of bacterial products such as lipopolysaccharide to activate Toll-like receptors. Upgraded regimen: Break local immune tolerance, while using own tumor cells mixed with human tumor cells of the same type GVAX subcutaneously, followed by live recombinant Listeria monocytogenes. During these treatments, Chinese medicine modulation has a certain augmentation effect.